Condition: Nasopharyngeal Cancinoma (NPC) · Sponsor: Hunan Cancer Hospital
This study aims to evaluate the efficacy and toxicity of adding low-dose radiotherapy to chemoimmunotherapy as a first-line treatment for nasopharyngeal carcinoma patients with liver metastasis.
This description comes directly from the study's public registry record.
Huai Liu, M.D. · +8673189762230 · liuhuai@hnca.org.cn
Always discuss trial participation with your own doctor first.
| Third Xiangya Hospital, Central South University, | Changsha, Hunan, China | Recruiting |
| Xiangya Hospital of Central South University | Changsha, Hunan, China | Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
| Hunan Cancer Hospital | Changsha, Hunan, China | Recruiting |
| The First People's Hospital of Chenzhou | Chenzhou, Hunan, China | Recruiting |
| Hunan University of Medicine General Hospital | Huaihua, Hunan, China | Recruiting |
| The Central Hospital of Shaoyang | Shaoyang, Hunan, China | Recruiting |
| Yueyang Central Hospital | Yueyang, Hunan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06788002